Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082.
Med Sci (Basel). 2018.
PMID: 30248938
Free PMC article.
Review.
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opio ā¦
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory ā¦